InsidersTradesSigma
申报总数
公司
▲ 买入（4 笔）
▼ 卖出（6 笔）
内部人交易记录
首席财务官已披露买入
4
已披露卖出
6
T+90 胜率
67%
T+90 平均收益
+31.9%
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the full record of transactions filed by Labrucherie Gil M, 首席财务官. Officer active across 5 companies, notably NEKTAR THERAPEUTICS. In total, 19 reports have been recorded. Split: 4 buys · 6 sells. Total volume traded: €995k. History available since 17 May 2021. The latest transaction was disclosed on 19 November 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Labrucherie Gil M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报19 总计
21,000 股0Common SharesSEC:0000912282-25-001279:0
9,000 股0Common SharesSEC:0000912282-25-000664:0
6,282 股@ US$5.5937.8% 占其流量Common StockSEC:0000950170-25-029330:0
标准退出：2025年5月26日 (T+90)
10,500 股@ US$5.50662.2% 占其流量Common StockSEC:0000950170-25-025039:0
标准退出：2025年5月20日 (T+90)
25,500 股0Common SharesSEC:0000912282-25-000184:0
40,763 股0Common StockSEC:0001962918-23-000034:0
28,750 股0Common StockSEC:0001209191-22-029899:0
52,631 股@ US$3.800.049% mcap50.0% 占其流量Common StockSEC:0001567619-22-009789:0
标准退出：2022年8月2日 (T+90)
52,631 股@ US$3.800.049% mcap50.0% 占其流量Common StockSEC:0001567619-22-009699:0
标准退出：2022年8月2日 (T+90)
7,579 股@ US$10.950.0031% mcap6.9% 占其流量Common StockSEC:0001209191-22-011436:0
52,950 股0Common StockSEC:0001209191-21-070690:0
21,149 股@ US$13.1646.3% 占其流量Common StockSEC:0001209191-21-065592:0
40,150 股0Common StockSEC:0001209191-21-065220:0
7,867 股@ US$13.8317.5% 占其流量Common StockSEC:0001209191-21-052384:0
7,898 股@ US$18.3022.5% 占其流量Common StockSEC:0001209191-21-034184:0
11,666 股Common StockSEC:0001209191-16-098173:0
11,666 股Common StockSEC:0001209191-16-098173:1
11,667 股Common StockSEC:0001209191-16-092942:0
11,667 股Common StockSEC:0001209191-16-092942:1
19 条申报中的 19 条
About Labrucherie Gil M
Labrucherie Gil M is Director Financier. He has 19 filings in total, and among the sampled recent filings, the transactions cover the period from 2016-01-21 to 2025-11-21, with buys of EUR 465456 and sells of EUR 529187. The companies mentioned are NEKTAR THERAPEUTICS, Rezolute, Inc., Septerna, Inc. and ACELYRIN, Inc., and the modal transaction nature is Attribution.
